29 results
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
/ C5aR pathway has been demonstrated to be beneficial or lifesaving in various pre-clinical models of viral lung injury and viral sepsis, including
6-K
EX-99.1
IFRX
InflaRx N.V.
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
response. Inhibition of the C5a / C5aR pathway has been demonstrated to be beneficial or lifesaving in various pre-clinical models of viral lung injury
6-K
EX-99.2
IFRX
InflaRx N.V.
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
Respiratory Neurology and related Rheumatology & related CVS & Acute injury Others
Page 9 Improved PK properties with higher plasma trough level
6-K
EX-99.1
IFRX
InflaRx N.V.
30 Aug 23
Current report (foreign)
8:00am
has been demonstrated to be beneficial or lifesaving in various pre-clinical models of viral lung injury and viral sepsis, including models
6-K
EX-99.1
6j5xke2k
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
424B5
skbp32
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
uhuw7lym
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
r5nstebbfr lret
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.2
2gqklrgf17k35g0e3i
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
424B5
vww40
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
z49p9pv
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
90m5 s88l2x
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
ixenls
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
424B5
sycgj6p5kmg 23h
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
hltp mlga1vmc9j
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
e7w0l
17 Jun 20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
7:30am